VAM
CORT icon

Visium Asset Management’s Corcept Therapeutics CORT Stock Holding History

Visium Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-28,188
Closed -$106K – 638
2015
Q3 		$106K Buy
+28,188
New +$143K ﹤0.01% 849

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Visium Asset Management's CORT Position: Q4 2015 in Review

Visium Asset Management sold out of Corcept Therapeutics (CORT) in Q4 2015, closing a stake of 28,188 shares — an estimated $106K sold.

Visium Asset Management first reported a position in CORT in Q3 2015 and held it in 1 quarter. The position peaked at $106K in Q3 2015. 97 funds tracked by Wall St. Rank hold CORT as of Q4 2015.

  • Visium Asset Management reported no remaining Corcept Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Visium Asset Management sold 28,188 Corcept Therapeutics shares in Q4 2015, an estimated $106K.
  • Visium Asset Management first reported a position in Corcept Therapeutics in Q3 2015 and held it in 1 quarter.
  • Visium Asset Management's Corcept Therapeutics position peaked at $106K in Q3 2015.
  • 97 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.